WE DETECT BIOTHREATS OF HIGH CONSEQUENCE AT THE POINT-OF-DECISION
AT PATIENT TESTING® is a registered trademark of BG Research Ltd (2025)
DELIVERING ACTIONABLE RESULTS,
AT THE POINT-OF-DECISION
- At Patient Testing represents a paradigm shift in molecular testing strategy
- Gold-standard real-time PCR results at the Point-of-Decision
- Focused molecular testing deployable to most environments
- Empowers healthcare professionals to make immediate clinical decisions
- Early detection with minimal delay promotes effective triaging, containment and treatment
- Providing localised molecular testing in communities
- Helps to bridge imbalances in access to molecular testing
INTELLIGENT MOLECULAR DETECTION PLATFORM
PORTABLE. RAPID. SENSITIVE.
- Rapid sample-to-result in under 30 minutes
- Sensitive and specific real-time PCR
- Portable and compact platform
- Simple and intuitive to use
- Minimal Full Economic Cost of testing
- Intelligent AI driven results calling
- Extraction free, direct detection of crude nasal, saliva, and blood samples
- Proprietary lyophilised assays with no cold-chain requirements
ONE HEALTH
UNIFIED TESTING. GLOBAL HEALTH SECURITY.
- Uniting disciplines, to prevent disease outbreaks at the animal-human-environment interface
- Global collaborative framework, to support pandemic preparedness and global health security
- Holistic cross-species surveillance
- Early detection and containment, of zoonotic diseases at their source
- Reduces risk of spillover, and onward cross-species disease transmission
- Sustainably balances and optimises human, animal and environmental health
- Building more resilient and equitable systems preventing future pandemics